Inverse relationship between plasminogen activator inhibitor-1 activity and adiponectin in overweight and obese women

Summary

Adipose tissue is an active endocrine organ secreting different adipokines such as plasminogen activator inhibitor-1 (PAI-1) and adiponectin, among many others. In this study, we investigated the association between PAI-1 activity and serum adiponectin levels in a group of 444 overweight and obese women and assessed the interrelationship with visceral adipose tissue (VAT; CT-scan L4-L5), insulin resistance (HOMA-IR), HDL cholesterol (HDL-chol) and inflammation (hs-CRP). PAI-1 was inversely related to adiponectin (r=-0.25, p<0.001; adjusted for age and BMI).After adjustment for age, VAT, HOMA-IR and hs-CRP, the relationship remained significant (r=-0.15; p=0.001), but disappeared after additional adjustment for HDL-chol (r=-0.09; p=0.067). Subjects were divided in two groups according to the median levels of adiponectin or PAI-1 levels. PAI-1 activity (19.1±11.4 vs. 15.8±8.6 AU/ml; p=0.003) and adiponectin levels (9.8±4.6 vs. 8.4±4.0 μg/ml; p<0.001) were significantly higher in the low adiponectin/PAI-1 groups. The difference in PAI-1 remained significant after adjustment for age and BMI (p=0.001), became borderline significant after adjustment for age and VAT (p=0.052), and disappeared after adjustment for age and HOMA-IR (p=0.116) or age and HDL-chol (p=0.443).The difference in adiponectin levels remained significant after adjustment for age, VAT, HOMA-IR and hs-CRP (p=0.006), but disappeared after additional adjustment for HDL-chol (p=0.089). Further analyses suggest a contribution of HOMA-IR and/or HDL-chol in the relationship between PAI-1 and adiponectin. HDL-chol was found to be the only factor independently determining both factors. In conclusion, in overweight and obese women, PAI-1 activity was inversely related to serum adiponectin, independent of visceral adipose tissue.

Keywords

Adiponectin - HDL cholesterol - insulin resistance - plasminogen activator inhibitor-1 - subclinical inflammation - visceral adipose tissue

• References

• 1 Alessi MC, Peiretti F, Morange P. et al Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
• 2 Maeda K. et al cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adi-Pose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
• 3 Mertens I. et al Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001; 33: 602-7.
• 4 Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 15: 1792-801.
• 5 Arita Y. et al Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
• 6 Weyer C, Funahashi T, Tanaka S. et al Hypoadiponectinemia in obesity and type 2 diabetes : close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
• 7 Hotta K. et al Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
• 8 Kumada M, Kihara S, Sumitsuji S. et al Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-9.
• 9 World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Geneva: 1999. WHO/NCD/NCS 99.2.
• 10 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
• 11 Anand SS, Yi Q, Gerstein H. et al Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 420-5.
• 12 Agewall S, Bokemark L, Wikstrand J. et al Insulin sensitivity and hemostatic factors in clinically healthy 58-year-old men. Thromb Haemost 2000; 84: 571-5.
• 13 Hulthe J. et al Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003; 52: 1612-4.
• 14 Choi KM, Lee J, Lee KW. et al Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol 2004; 61: 75-80.
• 15 Matsuzawa Y, Funahashi T, Kihara S. et al Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
• 16 Mertens I, Van Gaal LF. Visceral fat as a determinant of fibrinolysis and hemostasis. Semin Vasc Med 2005; 5: 48-55.
• 17 Ryan AS, Berman DM, Nicklas BJ. et al Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and adiposity. Diabetes Care 2003; 26: 2383-8.
• 18 Cnop M. et al Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-69.
• 19 Pellmé F, Smith U, Funahahsi T. et al Circulating adiponectin levels are reduced in nonobese but insulinresistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52: 1182-6.
• 20 Shetty GK, Economides PA, Horton ES. et al Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-7.
• 21 Winzer C, Wagner O, Festa A. et al Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004; 27: 1721-7.
• 22 Malyszko J. et al Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004; 89: 4620-7.
• 23 Skurk T, Van Harmelen V, Lee YM. et al Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients. Horm Metab Res 2002; 34: 659-63.
• 24 Maruyoshi H, Kojima S, Funahashi T. et al Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost 2004; 91: 1026-30.
• 25 Behre CJ, Fagerberg B, Hulten LM. et al The reciprocal association of adipocytokines with insulin resistance and C-reactive protein in clinically healthy men. Metabolism 2005; 54: 439-44.
• 26 Ouchi N. et al Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.
• 27 Lukaski HC. et al Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985; 41: 810-7.
• 28 Deurenberg P. et al Changes in fat-free mass during weight loss measured by bioelectrical impedance and by densitometry. Am J Clin Nutr 1989; 49: 33-6.
• 29 van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993; 17: 187-96.
• 30 Matthews DR, Hosker JP, Rudenski AS. et al Homeostasis model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
• 31 Ma LJ. et al Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-46.
• 32 Festa A. et al Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
• 33 Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998; 8: 335-8.
• 34 Maeda N. et al PPARγ ligands increase expression and plasma concentrations of adiponectin, an adiposederived protein. Diabetes 2001; 50: 2094-9.
• 35 Fasshauer M. et al Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-9.
• 36 Lihn AS. et al Increased expression of TNF-α, IL-6 and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003; 285: E1072-80.
• 37 Sakamato T, Woodcock-Mitchell J, Marutsuka K. et al TNF-α and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am J Physiol Cell Physiol 1999; 276: C1391-7.
• 38 Birgel M, Gottschling-Zeller H, Röhrig K. et al Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20: 1682-7.
• 39 Ouchi N. et al Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-63.
• 40 Kopp HP, Krzyzanowska K, Möhlig M. et al Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes Relat Metab Disord 2005; 29: 766-71.
• 41 Shah PK, Kaul S, Nilsson J. et al Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-83.